Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
CCC4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. (CCCC)

NASDAQ Global Select · Currency in USD
$3.06 ▼ -0.12 (-3.77%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.07 ▲ +0.01 (+0.33%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$3.18
Open
$3.15
Day's Range
$3.03 – $3.15
52 Week Range
$1.69 – $5.17
Volume
4,741,850
Avg. Volume
2,833,379
Market Cap
$376.46M
Beta (5Y Monthly)
3.08
PE Ratio (TTM)
--
EPS (TTM)
-$0.78
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$11.33

Profile: C4 Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
104
CEO
Andrew J. Hirsch

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.20 · Revenue est. $8.85M
DateEst.Actual
Aug 11, 2026-$0.23-$0.18Beat
May 12, 2026-$0.25-$0.20Beat
Feb 26, 2026-$0.31-$0.18Beat
Nov 6, 2025-$0.41-$0.44Miss
Aug 7, 2025-$0.38-$0.37Beat
May 6, 2025-$0.48-$0.37Beat

Analyst view

Consensus price target
$11.33 ▲ +270.3%
Range $6.00 – $20.00
Rating: Buy
Buy 71% · Hold 21% · Sell 7%

Get free alerts on CCCC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.